Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand.
Drugs. 2013 Jun;73(9):949-58. doi: 10.1007/s40265-013-0073-8.
Loteprednol etabonate ophthalmic gel 0.5% (Lotemax(®)) is approved in the USA for the treatment of post-operative inflammation and pain in patients who have undergone ocular surgery. The new gel formulation of loteprednol etabonate offers some potential advantages over the previously available ophthalmic suspension and ointment formulations of the drug. Because the gel is non-settling, a uniform dose of loteprednol etabonate is delivered without the need to vigorously shake the product. The pH of the gel formulation is close to that of physiological tears and the concentration of preservative is low. In clinical trials, loteprednol etabonate ophthalmic gel 0.5% for 14 days was effective, very well tolerated and safe when used for the treatment of post-operative inflammation and pain following cataract surgery. Relative to vehicle, loteprednol etabonate ophthalmic gel 0.5% effectively reduced postoperative ocular inflammation and ocular pain and had a similar overall tolerability, comfort and safety profile. It is associated with a low risk of inducing clinically significant increases in intraocular pressure. In conclusion, loteprednol etabonate ophthalmic gel 0.5% is an additional formulation option for the short-term treatment of post-operative inflammation and pain in patients who have undergone ocular surgery. It provides uniform dosing of a topical ophthalmic corticosteroid that has been demonstrated to be effective and well-tolerated in the treatment of ocular inflammation.
0.5% 卤替泼诺酯眼用凝胶（Lotemax(®)）在美国被批准用于治疗接受眼部手术后的炎症和疼痛。卤替泼诺酯的新凝胶制剂相对于先前可用的该药物的眼用混悬液和眼膏制剂具有一些潜在优势。由于凝胶不会沉降，因此无需剧烈摇晃产品即可提供均匀剂量的卤替泼诺酯。凝胶制剂的 pH 值接近生理泪液，且防腐剂浓度较低。在临床试验中，使用 0.5% 卤替泼诺酯眼用凝胶治疗白内障手术后的炎症和疼痛，14 天有效，耐受性良好，安全性高。与载体相比，0.5% 卤替泼诺酯眼用凝胶可有效减轻术后眼部炎症和疼痛，且总体耐受性、舒适度和安全性相似。它引起眼内压显著升高的风险较低。总之，0.5% 卤替泼诺酯眼用凝胶是用于治疗接受眼部手术的患者术后炎症和疼痛的另一种短期治疗选择。它提供了一种已被证明在治疗眼部炎症方面有效且耐受性良好的局部眼用皮质类固醇的均匀剂量。
